360º retinectomy effective for retinal detachment

Article

Virectomy with 360º retinectomy can be beneficial for the treatment of complex retinal detachments

It has been demonstrated that virectomy with 360º retinectomy can be beneficial for the treatment of complex retinal detachments, from recent research published in Retina.

Dr Anton Kolomeyer et al., Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, New Jersey, USA, reviewed the data of 41 eyes of 40 patients who underwent pars plana virectomy and 360º retinectomy for various reasons.

For 26 of the 41 eyes the main reason for surgery was retinal detachment after penetrating trauma. The outcome measures were complete retinal reattachment or attachment posterior to the scleral buckle. It was found that 11 eyes had recurrent retinal detachment and 7 received repeat pars plana virectomy with success in 6 of the eyes. The treatment was an anatomical success in 25 of 30 eyes and only 4 of the eyes had limited visual results.

The results show complex retinal detachment can be sufficiently managed by virectomy with 360º retinectomy.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.